Next Generation Solutions

AAHI's scientists apply a creative and pragmatic approach to protecting the world from disease, working to use our platform technologies to bring life-changing products to those who most need them.

WE ARE...

Eliminating cold chain requirements

Supporting local vaccine and immunotherapy production and self-reliance.

Enabling pandemic preparedness and rapid response.

Developing alternative routes of administration for needle-free delivery.

Working toward environmental sustainability.

Eliminating cold chain requirements

Our novel platforms enable temperature stable products that can be transported and stored at ambient temperatures.

Our novel freeze-dried saRNA/NLC vaccines can be stored for at least six months at ambient temperatures and up to a year in simple refrigeration, so they can be distributed to areas of unmet need, including those parts of the world without deep cold chain infrastructure.
We created innovative dry powder formulations of immune-stimulating adjuvants that remain stable at ambient temperatures for up to three months.

Supporting local vaccine and immunotherapy production and self-reliance.

Our immune-enhancing platforms use standard emulsion manufacturing technology and innovative and efficient manufacturing techniques that can be transferred to enable local production in low-and-middle income countries around the world.

Our technology transfer and training in adjuvant manufacturing techniques enables self-reliance, even in low-resource areas, and fosters local production and expanded availability of vaccines and immunotherapies.
Our NLC are produced with standard emulsification equipment and techniques to support global accessibility, including by eliminating the significant logistical difficulties that encumber production of Lipid Nanoparticles (LNPs) used with current RNA vaccines.

Enabling pandemic preparedness and rapid response.

Our adjuvant formulations and/or NLC can be made and stockpiled in readiness for combination with antigens or saRNA targeted to emerging threats.Our adjuvant formulations and/or NLC can be made and stockpiled in readiness for combination with antigens or saRNA targeted to emerging threats.

Our adjuvant formulations can be manufactured and stockpiled until they are needed. They can be stored for up to 2 years and then combined with the needed antigen or RNA construct.
Our NLCs can be manufactured and stored for at least a year under standard refrigeration, and then complexed with saRNA to elicit expression of the needed antigen.

Developing alternative routes of administration for needle-free delivery.

Our research demonstrates that intranasal administration of vaccines based on our platforms delivers strong mucosal immune responses, enhancing protection from respiratory diseases and potentially eliminating the need for needles.

AAHI’s dual agonist liposomal formulation combined with a protein antigen is safe and immunogenic when administered intranasally and shows protective efficacy against COVID and Amebiasis.
Based on the promising results of preclinical studies of our intranasal COVID saRNA vaccine candidate, BARDA is funding further collaboration to establish proof-of-concept for a dry powder, intranasally delivered (inhalable) saRNA vaccine for pandemic influenza.

Working toward environmental sustainability.

Our scientists are exploring ways in which we can reduce the burden on our ecosystem and precious natural resources by sourcing environmentally sustainable raw vaccine materials and developing ever more efficient ways in which to use those materials.

We reduce the amount of raw material required for effective vaccines. Our adjuvant formulation platform supports vaccines that use lower amounts of antigen for each dose, and our saRNA vaccine platform uses significantly lower doses of RNA than current RNA vaccines, t.
We are collaborating to develop alternatives to squalene, a key adjuvant ingredient in many vaccines, that is sourced from shark livers. There are currently 8 alternative oils and a plant-based alternative in development.
We developed a purification method that more efficiently extracts and purifies larger amounts of QS21, a saponin adjuvant, from limited supplies of the bark of Quillaja Saponaria, an endangered Chilean soapbark tree.